Entresto 50 mg combines sacubitril (24.3 mg) and valsartan (25.7 mg) to manage chronic heart failure, reducing the risk of cardiovascular death and hospitalization. Each package contains 28 film-coated tablets./Description: Entresto 50 mg is indicated for adult patients with symptomatic chronic heart failure with reduced ejection fraction. Sacubitril inhibits neprilysin, increasing levels of natriuretic peptides, leading to vasodilation and sodium excretion. Valsartan blocks angiotensin II receptors, reducing vasoconstriction and aldosterone secretion. Together, they improve cardiovascular outcomes by lowering blood pressure and decreasing heart strain.. Please Note that product description, color, ingredients, package and other information maybe different from the original pack kindly check the product for more accurate details.
